ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.61
0.20%
US Tech 100
18,112.40
1.54%
S&P 500
5,305.09
1.11%
US Dollar vs CAD
1.36051
-0.35%
Bitcoin
66,120.36
7.43%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) News

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DateTimeSourceHeadlineSymbolCompany
05/14/20247:00AMGlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
05/10/20243:00PMGlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
05/08/20243:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
05/07/20247:50AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
05/07/20246:29AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
05/07/20245:00AMGlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
04/29/20247:00AMGlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
04/23/20247:00AMGlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
04/07/20241:45PMGlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
04/01/20247:00AMGlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
03/26/20247:00AMGlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
03/25/20243:00PMGlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
03/22/20245:26PMBusiness WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
03/22/20242:10PMGlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
03/22/202410:04AMGlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
02/27/20248:19AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ESPREsperion Therapeutics Inc
02/27/20246:23AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
02/27/20245:00AMGlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
02/16/20243:30PMGlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
02/14/20241:14PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
02/14/20249:50AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
02/14/20247:42AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
02/14/20245:11AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
02/13/20247:00AMGlobeNewswire Inc.Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27NASDAQ:ESPREsperion Therapeutics Inc
02/01/20241:00PMGlobeNewswire Inc.RFK, Esperion Therapeutics Announce 2024 Promotional ScheduleNASDAQ:ESPREsperion Therapeutics Inc
01/23/20243:00PMGlobeNewswire Inc.Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesNASDAQ:ESPREsperion Therapeutics Inc
01/22/20245:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
01/22/20245:04AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
01/18/20248:15PMGlobeNewswire Inc.Esperion Announces Pricing of $85.1 Million Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
01/18/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Your Recent History

COIN
CASHEUR
TSX
HSH
Global X S&P 500 CAD Hed...
BIT
RNO
Renault
BIT
UB26GC
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved